Home Pharmaceuticals Asia Pacific Aesthetic Medicine Market Analysis, Share to [2022-2030]

Asia Pacific Aesthetic Medicine Market

Select Regional / Country Report

Asia Pacific Aesthetic Medicine Market Size, Share & Trends Analysis Report By Procedure Type (Invasive Procedures, Non-Invasive Procedures) and By Country(China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2022-2030

Report Code: SRPH3206DR
Study Period 2018-2030 CAGR 11.6%
Historical Period 2018-2020 Forecast Period 2022-2030
Base Year 2021 Base Year Market Size USD 105 Billion
Forecast Year 2030 Forecast Year Market Size USD 245 Billion
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global aesthetic medicine market was worth USD 105 billion in 2021 and is expected to expand to USD 245 billion by 2030, with a CAGR of 9.8% between 2022 and 2030.

Aesthetic treatments, often known as cosmetic treatments, are non-surgical procedures that are intended to reduce the appearance of wrinkles, renew the skin, and make it look younger. Fine line and wrinkle reduction, fat reduction, stretch mark cures, scar therapy, skin oxygenation and resurrection, body contouring and firming botulinum toxin, and skin repair are all covered under medical aesthetics. Aesthetic medicine is primarily concerned with modifying a person's visual look to their liking. Scars, excess fat, skin discoloration, skin laxity, moles, and wrinkles are all treated with this procedure.

A variety of invasive, minimally invasive, and non-invasive cosmetic procedures are used in aesthetic medicine. The global medical aesthetics market is growing as the elderly population becomes more aware of such treatments and accepts novel treatments. Furthermore, evolving consumer attitudes around wellness, beauty, and healthy aging have increased aesthetic awareness and acceptability, boosting demand from new patient categories like men and millennials.

By 2030, with an expected valuation of USD 60455 million, Asia Pacific will be the second-largest market for aesthetic medicines. For the period of 2022 to 2030, the CAGR of aesthetic medicines is expected to be 11.6% for the Asia-Pacific market.

Market Dynamics

Asia Pacific Aesthetic Medicine Market Drivers

Rhinoplasty, facelifts, neck lifts, eyelid surgery, and eye lifts have all seen a considerable increase in popularity. According to an Allergan poll conducted in April 2020, 95% of respondents said they planned to use a neurotoxic filler treatment once COVID-19 restrictions are lifted. According to the same report, 86% of private cosmetic clinics in China reopened in the third quarter of 2020, with a 52% increase in patient traffic. This signalled that the market was on the rise.

Cosmetic surgery is becoming more popular, while traditional insurance-based care is seeing a decline in payments. Medical aesthetic activities include delivering cosmetic operations in doctors' offices or working in medical spas, and they are practiced by health professionals from all professions.

Minimally invasive operations offer benefits such as smaller incisions, shorter hospital stays, faster wound healing, less discomfort, fewer open wounds, and a lower risk of complications when compared to traditional surgeries. Minimally invasive surgeries are quickly displacing invasive operations.

In the Asia Pacific Due to an increase in the number of breast augmentations and other aesthetic surgical operations, the female sector will account for roughly 75.4% of the market in 2020. Furthermore, rising demand for facial aesthetic operations among women, such as injectables and skin rejuvenation surgeries for cheek enlargement, nasolabial folds, and nose contouring, would boost market growth.

Between the ages of 25 and 30, wrinkles, loss of skin suppleness, and dark spots appear, and between the years of 30 and 65, wrinkles, loss of skin suppleness, and dark patches become more evident. As a result, a large population vulnerable to various indications of ageing is driving up demand for aesthetic medicines. In China, roughly 46.81% of the total population was aged 25 to 54 in 2020.  As a result, the market for aesthetic medicine is predicted to expand at a constant rate among adults aged 25 to 65.

In 2020, China's aesthetic medicine market had a revenue share of more than 17%. The country's market demand will be boosted by rising obesity rates, an increase in the number of breast reconstruction procedures, and increased awareness of aesthetic procedures. The market will rise due to the rising demand for facial aesthetics among teenagers and the elderly population. Furthermore, the presence of numerous local players in China who are investing in developing a wider range of fillers and energy-based devices would hasten market expansion.

Asia Pacific Aesthetic Medicine Market Restraints

Due to increased internet purchases, the cosmeceuticals (self-care) market had a slight effect during the pandemic. Invasive and minimally invasive needs, such as aesthetic operations, saw a significant impact as a result of aesthetic facility closures and appointment postponements. The non-invasive market, which includes injectable fillers and laser-based cosmetic treatments, has experienced moderate-to-high consequences but is predicted to recover at a moderate-to-high rate.

During the pandemic, there has been a rise in demand for home skincare equipment. Philips' at-home Intense Pulse Light (IPL) hair removal system, for example, saw an increase in sales, with strong demand in APAC. Manufacturing firms in Taiwan and South Korea had to reduce production for components of laser-based devices in the first two quarters of 2020, according to Wiley One Library, affecting the supply chain. As a result, production for 2020 was lower.

Private and government insurance policies may not cover all aesthetic operations. Methods primarily aimed at removing wrinkles, fats, hair, tattoos,  extra skin, and liposuction for the purpose of improving one's external appearance are not covered. Medicines include facial reconstructive surgery after an accident and weight loss surgery to alleviate obesity-related concerns. The percentage of surgical treatments justified by medical reasons is smaller than the percentage of procedures undertaken for cosmetic reasons. As a result, a lack of reimbursement coverage for most operations may limit the market's total growth.

Asia Pacific Aesthetic Medicine Market Opportunities

During the projected period, technological advancements provide attractive prospects for market participants. Furthermore, the critical need for optimising imaging workflows will boost the aesthetic medicine market's future growth rate.

Report Scope

Report Metric Details
Segmentations
By Procedure Type
  1. Invasive Procedures
    1. Breast augmentation,
    2. Liposuction
    3. Nose reshaping
    4. Eyelid
    5. surgery
    6. Tummy tuck
    7. Others
  2. Non-Invasive Procedures
    1. Botulinum toxin type A
    2. Soft tissue fillers
    3. Chemical peel
    4. Laser hair removal
    5. Microdermabrasion
Company Profiles Evolus Inc. AIVITA Biomedical Ellman International, Inc. Genesis Biosystems, Inc. Lumenis Ltd. Sciton, Inc. Wells Johnson Company Zeltiq Aesthetics, Inc.
Geographies Covered
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Top Key Players

Evolus Inc. AIVITA Biomedical Ellman International, Inc. Genesis Biosystems, Inc. Lumenis Ltd. Sciton, Inc. Wells Johnson Company Zeltiq Aesthetics, Inc. Others

Frequently Asked Questions (FAQs)

What is the estimated growth rate (CAGR) of the Asia Pacific Aesthetic Medicine Market?
The market size is growing at a CAGR of 11.6% from 2020 to 2030.
Breast augmentations and other aesthetic surgical operations, the female sector is the key driver for the growth of this market.
The key players in this market are Evolus Inc., AIVITA Biomedical, Ellman International, Inc., Genesis Biosystems, Inc., Lumenis Ltd., Sciton, Inc., Wells Johnson Company, Zeltiq Aesthetics, Inc.
The Projected value of this market is USD 245 billion by 2030.


We are featured on :

This website uses cookies to ensure you get the best experience on our website. Privacy Policy